Aloke Finn
Latest contributions
Preventing distal particles embolization after DCB angioplasty
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Aloke Finn and Antonio Colombo share their insights on a specific and often overlooked complication of drug-coated balloon (DCB) angioplasty: particulate embolization.
They begin by clarifying the distinction between this phenomenon and traditional distal embolization, explaining that particulate embolization is iatrogenic and device-related—it is...
Treating complex CAD indications with sirolimus coated balloon: evidence and performance
22 May 2025 – From EuroPCR 2025
Gain a deeper understanding of how sirolimus coated balloon (SCB) technology is shaping the treatment of complex coronary artery disease (CAD). This EuroPCR 2025 session brings together compelling clinical trial data and real-world case presentations to illustrate the safety, efficacy, and versatility of the MagicTouch SCB...
Transforming PCI: mastering the implementation of drug-eluting balloons
22 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session provides a comprehensive overview of drug-eluting balloons (DEBs) and their growing role in percutaneous coronary intervention (PCI). Gain a clear understanding of the clinical evidence and rationale supporting DEBs, including how these devices minimize metal implantation and effectively treat both standard and...
The ARC consensus on DCB - evidence-based DCB technology
15 May 2024 – From EuroPCR 2024
In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.
Sirolimus-coated balloon: expanding the scope of indications for complex coronary artery disease treatment
14 May 2024 – From EuroPCR 2024
Watch this session to gain case-based insights on using DCBs in complex settings. Learn valuable tips and tricks for optimal DCB application, including the best timing and situations for their use. Discover how to effectively implement a hybrid strategy that combines DES and DCB when needed.
Sirolimus coated balloon and coronary artery disease: expanding the treatment indications
17 May 2022 – From EuroPCR 2022
Through a case presentation, as well as upcoming studies and rationale for the Food and Drug Administration, the aim of this EuroPCR 2022 session is to help you answer the following questions: how can the use of a sirolimus-coated DCB be expanded in new and challenging treatment indications? Why is...
MagicTouch sirolimus coated balloon continues to be the choice of treatment for CAD
19 May 2021 – From EuroPCR 2021
Watch this session presented by Antonio Colombo, Aloke Finn, Sandeep Basavarajaiah, Gianluca Caiazzo and Bernardo Cortese in order to know where to use a DCB in today's clinical practice, to learn about real-world case-based experience and interesting data presentation from various registries and clinical studies, and to understand the technology...
Truths and myths about renal denervation
A session at EuroPCR 2019 was dedicated to the truths and myths surrounding renal denervation. Does ablation location matter? Is safe and successful denervation as simple as measuring ablation depth? Should renal denervation be avoided in patients with isolated hypertension? Is the effect of renal denervation...
Myth busters – Truth or myth? Facts and data about renal denervation
22 May 2019 – From EuroPCR 2019
Consult this session to learn more about the fundamentals of radio-frequency ablation, the factors that may affect responders to renal denervation and the advancement of the renal denervation procedure.
Future and scope of sirolimus-coated balloon in peripheral vascular treatment
22 May 2019 – From EuroPCR 2019
Consult this session to learn more about the emerging sirolimus-coated balloon (SCB) technology in peripheral vascular treatment. Discover the SCB with NANOLUTE technology clinical outcome in below-the-knee (BTK) and superficial femoral artery (SFA) indications, and in arteriovenous fistula (AVF) and arteriovenous graft (AVG) indications.
Why you should treat your PCI patients with the COMBO Plus stent – Insight from clinical-based evidence
22 May 2019 – From EuroPCR 2019
Consult this session to learn how COMBO Plus stent's unique design meets your clinical requirements, in all comers and high risk populations (ACS, Left Main PCI, etc.).
Transforming DCB strategy: sirolimus-coated balloon with Nanolute technology
21 May 2019 – From EuroPCR 2019
Consult this session on DCB strategy to learn more about the use of sirolimus-coated balloon with Nanolute technology, and to understand its benefits and its future applications in coronary interventions, thanks to the insight from pre-clinical evaluation, various clinical cases and FDA study.
Presentations by the Jon DeHaan Foundation Grant applicants
20 May 2019 – From PCR Innovators Day 2019